ℹ️
🇬🇧
Search
Search for people relevant for "therapeutic drug monitoring"
therapeutic drug monitoring
Person
Class
Person
Publication
Programmes
Export current view
MUDr. Petr Smíšek
External person at Second Faculty of Medicine
59 publications
Publications
publication
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study
2020 |
Second Faculty of Medicine
publication
Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial
2018 |
Publication without faculty affiliation
publication
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
2024 |
Second Faculty of Medicine
publication
The effect of chemotherapy on cognitive functions in children with leukemia
2023 |
First Faculty of Medicine, Second Faculty of Medicine
publication
Recommendations of the Czech Society of Haematology for the diagnosis and treatment of immune thrombocytopenia in adults
2023 |
Central Library of Charles University
publication
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia
2022 |
Publication without faculty affiliation
publication
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study
2022 |
Publication without faculty affiliation
publication
Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach
2022 |
Publication without faculty affiliation
publication
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
2022 |
Publication without faculty affiliation
publication
A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS
2021 |
Second Faculty of Medicine
Load more publications (49)
Loading network view...